CellaVision AB (publ) (CEVI.ST)
SEK 222.0
(2.07%)
SEK 222.0
(2.07%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 677.29 Million SEK | 5.94% |
| 2022 | 639.34 Million SEK | 13.05% |
| 2021 | 565.55 Million SEK | 19.96% |
| 2020 | 471.44 Million SEK | 2.09% |
| 2019 | 461.77 Million SEK | 26.58% |
| 2018 | 364.81 Million SEK | 17.94% |
| 2017 | 309.31 Million SEK | 16.7% |
| 2016 | 265.03 Million SEK | 10.71% |
| 2015 | 239.39 Million SEK | 10.36% |
| 2014 | 216.91 Million SEK | 20.61% |
| 2013 | 179.85 Million SEK | 6.1% |
| 2012 | 169.51 Million SEK | 9.08% |
| 2011 | 155.4 Million SEK | 18.05% |
| 2010 | 131.63 Million SEK | 20.8% |
| 2009 | 108.97 Million SEK | 8.49% |
| 2008 | 100.44 Million SEK | 34.71% |
| 2007 | 74.56 Million SEK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 187.79 Million SEK | 10.41% |
| 2024 Q1 | 170.08 Million SEK | -15.23% |
| 2024 Q3 | 178.65 Million SEK | -4.87% |
| 2023 Q4 | 200.63 Million SEK | 19.5% |
| 2023 Q2 | 169.66 Million SEK | 21.98% |
| 2023 FY | 677.29 Million SEK | 5.94% |
| 2023 Q1 | 139.09 Million SEK | -8.68% |
| 2023 Q3 | 167.89 Million SEK | -1.04% |
| 2022 Q4 | 152.31 Million SEK | 8.0% |
| 2022 FY | 639.34 Million SEK | 13.05% |
| 2022 Q1 | 162.42 Million SEK | -1.06% |
| 2022 Q2 | 183.57 Million SEK | 13.02% |
| 2022 Q3 | 141.02 Million SEK | -23.18% |
| 2021 Q2 | 135.45 Million SEK | 1.12% |
| 2021 Q4 | 164.16 Million SEK | 24.38% |
| 2021 Q1 | 133.95 Million SEK | 2.26% |
| 2021 FY | 565.55 Million SEK | 19.96% |
| 2021 Q3 | 131.98 Million SEK | -2.56% |
| 2020 Q1 | 134.43 Million SEK | -10.28% |
| 2020 Q4 | 130.99 Million SEK | 48.89% |
| 2020 FY | 471.44 Million SEK | 2.09% |
| 2020 Q3 | 87.97 Million SEK | -25.47% |
| 2020 Q2 | 118.04 Million SEK | -12.19% |
| 2019 Q2 | 112.44 Million SEK | 8.24% |
| 2019 Q3 | 95.59 Million SEK | -14.98% |
| 2019 Q1 | 103.89 Million SEK | -6.37% |
| 2019 FY | 461.77 Million SEK | 26.58% |
| 2019 Q4 | 149.83 Million SEK | 56.73% |
| 2018 Q1 | 77.61 Million SEK | 1.95% |
| 2018 FY | 364.81 Million SEK | 17.94% |
| 2018 Q4 | 110.96 Million SEK | 31.57% |
| 2018 Q3 | 84.33 Million SEK | -8.23% |
| 2018 Q2 | 91.89 Million SEK | 18.41% |
| 2017 Q4 | 76.13 Million SEK | 24.1% |
| 2017 Q1 | 93.14 Million SEK | 28.02% |
| 2017 Q2 | 78.68 Million SEK | -15.53% |
| 2017 Q3 | 61.34 Million SEK | -22.03% |
| 2017 FY | 309.31 Million SEK | 16.7% |
| 2016 Q4 | 72.76 Million SEK | 6.53% |
| 2016 FY | 265.03 Million SEK | 10.71% |
| 2016 Q2 | 65.72 Million SEK | 12.83% |
| 2016 Q3 | 68.3 Million SEK | 3.93% |
| 2016 Q1 | 58.25 Million SEK | -5.37% |
| 2015 Q4 | 61.55 Million SEK | -17.41% |
| 2015 Q3 | 74.52 Million SEK | 44.76% |
| 2015 Q2 | 51.48 Million SEK | -0.65% |
| 2015 FY | 239.39 Million SEK | 10.36% |
| 2015 Q1 | 51.82 Million SEK | -28.5% |
| 2014 Q1 | 43.23 Million SEK | -33.36% |
| 2014 FY | 216.91 Million SEK | 20.61% |
| 2014 Q4 | 72.48 Million SEK | 54.08% |
| 2014 Q3 | 47.04 Million SEK | -13.13% |
| 2014 Q2 | 54.15 Million SEK | 25.25% |
| 2013 Q2 | 36.09 Million SEK | 6.81% |
| 2013 Q3 | 45.07 Million SEK | 24.88% |
| 2013 Q4 | 64.88 Million SEK | 43.95% |
| 2013 FY | 179.85 Million SEK | 6.1% |
| 2013 Q1 | 33.79 Million SEK | -32.95% |
| 2012 Q4 | 50.4 Million SEK | 42.66% |
| 2012 Q1 | 40.41 Million SEK | -12.98% |
| 2012 Q2 | 43.36 Million SEK | 7.29% |
| 2012 Q3 | 35.33 Million SEK | -18.51% |
| 2012 FY | 169.51 Million SEK | 9.08% |
| 2011 Q3 | 36.45 Million SEK | -12.97% |
| 2011 FY | 155.4 Million SEK | 18.05% |
| 2011 Q4 | 46.44 Million SEK | 27.4% |
| 2011 Q1 | 30.61 Million SEK | -26.91% |
| 2011 Q2 | 41.88 Million SEK | 36.81% |
| 2010 Q2 | 36.64 Million SEK | 73.46% |
| 2010 Q3 | 31.98 Million SEK | -12.69% |
| 2010 Q1 | 21.12 Million SEK | -46.28% |
| 2010 FY | 131.63 Million SEK | 20.8% |
| 2010 Q4 | 41.88 Million SEK | 30.94% |
| 2009 Q3 | 26.99 Million SEK | 30.38% |
| 2009 Q1 | 21.95 Million SEK | -42.7% |
| 2009 Q4 | 39.31 Million SEK | 45.66% |
| 2009 Q2 | 20.7 Million SEK | -5.72% |
| 2009 FY | 108.97 Million SEK | 8.49% |
| 2008 FY | 100.44 Million SEK | 34.71% |
| 2008 Q2 | 22.8 Million SEK | 0.0% |
| 2008 Q3 | 20.79 Million SEK | -8.81% |
| 2008 Q4 | 38.32 Million SEK | 84.27% |
| 2007 FY | 74.56 Million SEK | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Acarix AB (publ) | 6.24 Million SEK | -10752.299% |
| ADDvise Group AB (publ) | 1.37 Billion SEK | 50.671% |
| ADDvise Group AB (publ) | 1.37 Billion SEK | 50.671% |
| Arcoma AB | 163.01 Million SEK | -315.478% |
| Bactiguard Holding AB (publ) | 203.99 Million SEK | -232.022% |
| BICO Group AB (publ) | 2.23 Billion SEK | 69.757% |
| Boule Diagnostics AB (publ) | 571.32 Million SEK | -18.547% |
| Clinical Laserthermia Systems AB (publ) | 8.27 Million SEK | -8086.776% |
| Chordate Medical Holding AB (publ) | 976.28 Thousand SEK | -69274.698% |
| C-Rad AB (publ) | 424.61 Million SEK | -59.507% |
| Duearity AB (publ) | 1.65 Million SEK | -40848.73% |
| Dignitana AB (publ) | 86.06 Million SEK | -686.972% |
| Episurf Medical AB (publ) | 10.3 Million SEK | -6475.65% |
| Getinge AB (publ) | 31.82 Billion SEK | 97.872% |
| Scandinavian Real Heart AB (Publ) | - SEK | -Infinity% |
| Iconovo AB (publ) | 7.07 Million SEK | -9468.585% |
| Integrum AB (publ) | 104.11 Million SEK | -550.5% |
| Luxbright AB (publ) | 854.69 Thousand SEK | -79143.336% |
| Mentice AB (publ) | 273.61 Million SEK | -147.539% |
| OssDsign AB (publ) | 112.15 Million SEK | -503.878% |
| Paxman AB (publ) | 210.11 Million SEK | -222.34% |
| Promimic AB (publ) | 37.07 Million SEK | -1727.062% |
| Qlife Holding AB (publ) | 244 Thousand SEK | -277478.689% |
| SciBase Holding AB (publ) | 23.24 Million SEK | -2813.71% |
| ScandiDos AB (publ) | 60.42 Million SEK | -1020.806% |
| Sectra AB (publ) | 2.96 Billion SEK | 77.146% |
| Sedana Medical AB (publ) | 153.86 Million SEK | -340.18% |
| Senzime AB (publ) | 35.75 Million SEK | -1794.311% |
| SpectraCure AB (publ) | 318 Thousand SEK | -212884.906% |
| Stille AB | 294.89 Million SEK | -129.674% |
| Vitrolife AB (publ) | 3.51 Billion SEK | 80.715% |
| Xvivo Perfusion AB (publ) | 597.54 Million SEK | -13.346% |